Please ensure Javascript is enabled for purposes of website accessibility

A Crazy, but True, Fact About Cronos Group That Investors Need to Know

By Sean Williams - May 8, 2019 at 6:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cronos may have the third-largest market cap of any pot stock, but it's not the major player it's being made out to be.

Just when you think it couldn't get any better for marijuana stock investors, the industry just keeps proving skeptics wrong. Following an abysmal fourth quarter that saw some pot stocks lose half of their value, the Horizons Marijuana Life Sciences ETF, the first tradable cannabis exchange-traded fund, is up more than 50% year to date, with many well-known marijuana stocks at or near all-time highs.

It's certainly easy to get excited about the long-term "pot-tential" for the industry when analysts like Christopher Carey at Bank of America are throwing around utopic peak annual revenue projections of $166 billion, and forecasting that cannabis will disrupt other industries that are generating a collective $2.6 trillion in annual sales.

An up-close view of a flowering cannabis plant growing in a large indoor farm.

Image source: Getty Images.

This cash-rich pot stock is a popular choice among investors

This excitement is a big reason behind the rise of Cronos Group (CRON -0.64%), one of the most popular pot stocks. As of this past weekend, Cronos was the third-largest marijuana stock by market cap, at $5.55 billion.

Of course, in all fairness, Cronos Group's biggest boost came from the announcement in December (and closure in March) of a $1.8 billion equity investment from tobacco company Altria (MO -0.48%).

Altria, which has been contending with a precipitous decline in tobacco shipment volumes, has seen the U.S. adult smoking rate dip to a more-than-50-year low of 14%. In order to continue growing its business, it has had to lean heavily on its premium Marlboro brand and, more specifically, price hikes. Not wanting to run the risk of pricing consumers out of the market for its premium product, Altria needs new sales channels. The Cronos investment, which gave Altria a 45% non-diluted stake in the company, should allow the duo to work on pre-rolled and vape products, among other initiatives, and it gives Altria, which is a cash-flow machine, the opportunity to acquire Cronos Group at some point down the line.

As for Cronos, it walked away from this investment with $1.82 billion in cash on its balance sheet after having ended the previous quarter with around $24 million. It now has the capital to consider expanding its production capacity, to diversify its product portfolio, or to move into new markets.

This cash buffer and its tie-in with Altria are a big reason behind the success of Cronos Group's stock.

A processor using scissors to trim cannabis flowers.

Image source: Getty Images.

A scary truth about Cronos Group

However, Cronos Group shareholders and investors might be overlooking one of the craziest but truest facts about this company. Namely, that if you look at marijuana growers as retailers of their product, Cronos may not even be a top 10 player in Canada.

Although peak production estimates change all the time, here's a quick rundown of the 11 companies that should produce at least 100,000 kilos when operating at full capacity, as of right now.

  1. Aurora Cannabis: More than 625,000 kilos (company estimate)
  2. Canopy Growth: More than 500,000 kilos
  3. Aphria: 255,000 kilos (company estimate)
  4. CannTrust Holdings: 200,000 kilos to 300,000 kilos (company estimate)
  5. The Green Organic Dutchman: 219,000 kilos (company estimate)
  6. HEXO: 150,000 kilos (company estimate)
  7. Aleafia Health: 138,000 kilos (company estimate)
  8. Cronos Group: 117,500 kilos (company estimate)
  9. OrganiGram Holdings (OGI 2.83%): 113,000 kilos (company estimate)
  10. Tilray: More than 100,000 kilos
  11. Emerald Health Therapeutics (EMHT.F 6.11%): More than 100,000 kilos

As you'll see from this list of individual growers, Cronos Group slides in as the eighth-largest producer, with all but three of these marijuana growers providing peak production estimates.

A person holding a magnifying glass over a potted cannabis plant.

Image source: Getty Images.

But something interesting happens if you look at these producers as retailers that also need to sell their product (which is the case). For example, the Pure Sunfarms initiative, which is a joint venture between Emerald Health Therapeutics and Village Farms International, will be capable of 150,000 kilos of yearly production by the midpoint of 2020. Also, this doesn't take into account that Emerald Health has the option to convert another 2.6 million square feet of vegetable-growing greenhouses owned by Village Farms into cannabis grow sites. That makes the Pure Sunfarms joint venture a bigger player than Cronos Group's aggregate production.

We can also bring Auxly Cannabis Group (CBWTF -9.33%) into the mix. Auxly Cannabis wasn't included in the above list of growers because it has both wholly owned grow farms, as well as royalty interests with licensed producers. These royalty deals allow Auxly to provide upfront capital to growers looking to expand capacity in return for a percentage of crop yield at a below-market cost. When all of Auxly's more than one dozen partners are producing at full capacity (probably by early 2021), it'll be selling a company-estimated 170,000 kilos a year. That, too, is more than Cronos will bring to market each year.

And then there's OrganiGram Holdings, which has just a single grow site at Moncton, New Brunswick. Even though OrganiGram has stuck by its peak output estimate of 113,000 kilos for more than a year, investors might forget that the entire reason the company chose to bolster its phase 4 expansion, as announced in March 2018, was because of higher-than-expected yields from its harvests. If OrganiGram's yields are even 4% better than advertised, it too could be a bigger player than Cronos Group.

Thus, when it comes to production and, more importantly, the retail sale of cannabis products, Cronos Group is, at best, a top 10 fringe player, or maybe not even top 10 material. Period. That's an eye-opener for a company with the third-largest market cap of any marijuana stock, and which has an unimpressive overseas presence at the moment.

Chalk this up as just another reason why I believe Cronos to be the most overvalued of all pot stocks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
$3.09 (-0.64%) $0.02
Altria Group, Inc. Stock Quote
Altria Group, Inc.
$43.19 (-0.48%) $0.21
OrganiGram Holdings Stock Quote
OrganiGram Holdings
$1.09 (2.83%) $0.03
Emerald Health Therapeutics, Inc. Stock Quote
Emerald Health Therapeutics, Inc.
$0.04 (6.11%) $0.00
Auxly Cannabis Group Inc. Stock Quote
Auxly Cannabis Group Inc.
$0.07 (-9.33%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.